Siglec-15: An Attractive Immunotherapy Target

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Siglec-15 is identified as a critical mediator of immune suppression within the tumor microenvironment.
• The tumor microenvironment's immunosuppressive nature poses a significant challenge in cancer therapy.

Discussion:

• NC318, a monoclonal antibody targeting Siglec-15, is being evaluated in a Phase I clinical trial.
• This approach aims to overcome immune evasion mechanisms employed by tumors.

Key Insights:

• The Phase I trial of NC318 demonstrated encouraging efficacy signals.
• A notable complete response was observed in a patient with non-small cell lung cancer (NSCLC).
• This patient's NSCLC was refractory to prior PD-1 blockade therapy, highlighting a potential new treatment avenue.

Outlook:

• Siglec-15 inhibition represents a promising therapeutic strategy for overcoming resistance to existing immunotherapies.
• Further investigation into NC318 is warranted to explore its potential in broader patient populations and cancer types.